Lilly, however, noted that a pre-specified secondaryanalysis of pooled data showed statistically significant slowing of cognitive decline in patients with mild-to-moderate disease who were treated with its solanezumab compound.
While the primary endpoints of the two pivotal studies conducted were not met, a secondaryanalysis of the data demonstrated that a molecule acting specifically on amyloid-beta can slow cognitive decline in patients with mild AD.